Company: Gilead Sciences Inc. (GILD)
*DRIP Club Members are able to acquire or list a share of a company on the DRIP Exchange Page.
Company Profile: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology. -Morningstar.com-
Symbol: GILD
Recent Price: $74.98
Dividends: $3.08
Yield: 4.11%
Sector: Healthcare
Industry: Drug Manufacturers-General
Address & Company Phone #: 333 Lakesi Drive FOSTER CITY CA 94404, 650-574-3000
Transfer Agent: Computershare 800-942-5909
Moody’s Rating: A3
Minimum & Maximum Investment: $10 – $250,000/year
Investment Dates: Weekly
Shares to Qualify: 1 Share or $25
Fees: Div.: 5% of amount invested up to $5 Max Cash: $5+5¢/sh. Cert: Sells: by Mail, Phone or Internet for $25+12¢/sh.
52 Week High & Low: $87.87, $62.07